Complex Injectable Market Report 2026

The complex injectable market size has grown rapidly in recent years. It will grow from $19.77 billion in 2025 to $22.05 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to increasing prevalence of chronic and complex diseases, advancements in injectable drug delivery technologies, expansion of hospital-based injectable treatments, rising adoption of biologics, improvements in sterile manufacturing capabilities.

The complex injectable market size is expected to see rapid growth in the next few years. It will grow to $33.75 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to increasing investments in complex injectable pipelines, rising demand for oncology and specialty injectables, expansion of contract manufacturing services, growing focus on self-administered injectables, increasing regulatory approvals for advanced formulations. Major trends in the forecast period include increasing demand for sterile injectable drug products, rising development of biologic and advanced injectable therapies, growing use of high-precision manufacturing processes, expansion of antibody-drug conjugate injectables, enhanced focus on cold-chain compatible formulations.

The rising prevalence of chronic diseases is expected to drive the growth of the complex injectable market in the coming years. Chronic diseases are long-term medical conditions that generally develop gradually and require continuous management. The increasing prevalence of chronic diseases is attributed to factors such as aging populations, as older individuals are more prone to long-term conditions like diabetes, heart disease, and arthritis. Complex injectables aid in managing chronic diseases by delivering targeted medications that alleviate symptoms and slow disease progression. For example, according to the Office for Health Improvement & Disparities (OHID), a UK-based public health agency, the global number of adults with diabetes is projected to increase from 537 million in 2021 to 643 million by 2030. Consequently, the rising prevalence of chronic diseases supports growth in the complex injectable market.

Major companies operating in the drug delivery systems market are emphasizing innovations in drug delivery methods, such as autoinjector dosage forms, to enhance patient convenience, promote adherence to therapy, ensure accurate and safe drug administration, and facilitate the effective delivery of complex biologic treatments. Autoinjector dosage forms are pre-filled, self-administered injection devices designed to deliver a precise medication dose safely and conveniently, commonly used for biologics and other complex therapies. For example, in January 2024, Taisho Pharmaceutical Co. Ltd., a Japan-based generic drug manufacturer, introduced Nanozora 30 mg for subcutaneous injection, providing a patient-friendly device designed for easy self-administration. The product ensures safety with a needle-covering feature to prevent accidental needle sticks and enables patients with rheumatoid arthritis to receive treatment conveniently once every four weeks. This broadens Taisho’s treatment offerings alongside its previously available syringe formulation.

In April 2024, Eli Lilly And Company, a US-based pharmaceutical firm, acquired Nexus Pharmaceuticals Inc. for an undisclosed sum. Through this acquisition, Eli Lilly enhances its parenteral (injectable) manufacturing capabilities by incorporating a state-of-the-art sterile facility from Nexus Pharmaceuticals. This initiative boosts Lilly’s ability to meet the increasing demand for complex injectable medications and supports its extensive pipeline for conditions such as diabetes, obesity, and migraine. Nexus Pharmaceuticals Inc. is a US-based pharmaceutical company engaged in the development and production of generic and specialty injectable drugs.

Major companies operating in the complex injectable market are Johnson & Johnson Pharmaceutical, Merck & Co. Inc., Pfizer Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Novo Nordisk, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim GmbH, Baxter Healthcare Corporation, Fresenius Kabi, Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Indivior PLC, Amphastar Pharmaceuticals Inc., Braun Melsungen AG, Ferring Pharmaceuticals, Oakwood Labs, ForDoz Pharma.

North America was the largest region in the complex injectable market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the complex injectable market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the complex injectable market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the complex injectable market by increasing costs of imported sterile manufacturing equipment, glass vials, syringes, active pharmaceutical ingredients, and specialized packaging materials. North America and Europe are most affected due to reliance on global supply chains for injectable-grade components, while Asia-Pacific faces cost pressures on export-oriented manufacturing. These tariffs are raising production costs and affecting supply consistency. However, they are also encouraging domestic sterile manufacturing expansion, local packaging production, and greater investment in regional injectable manufacturing capacity.

The complex injectable market research report is one of a series of new reports that provides complex injectable market statistics, including complex injectable industry global market size, regional shares, competitors with a complex injectable market share, detailed complex injectable market segments, market trends and opportunities, and any further data you may need to thrive in the complex injectable industry. This complex injectable market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Complex injectables are advanced pharmaceutical products that need precise formulation and sterile manufacturing processes for injection. They are used to administer targeted therapies, vaccines, or biologics directly into the body, addressing diseases that cannot be effectively treated with standard oral medications.

The primary product categories of complex injectables include monoclonal antibodies, gene therapies, vaccines, proteins and peptides, and antibody-drug conjugates (ADCs). Monoclonal antibodies are laboratory-engineered molecules designed to replicate the immune system’s ability to identify and attach to specific antigens. They are applied across multiple therapeutic areas such as oncology, diabetes, autoimmune disorders, neurological disorders, cardiovascular diseases, and infectious diseases, with various administration methods including intravenous (IV), subcutaneous (SC), intramuscular (IM), epidural, and intradermal. These products are distributed through channels such as direct sales, pharmacies, e-commerce platforms, distributors, and wholesalers, with primary end users including hospitals, ambulatory surgical centers, specialty clinics, home healthcare providers, and research institutions.

The complex injectable market consists of sales of liposomal injections, depot injections, nanoparticle-based injectables, emulsions, and suspensions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.